Piramal Healthcare overpriced, but a good buy: Shrikanth Shetty

Shrikanth Shetty, Head, Equity Advisory, Unicon Investment Solutions, in an interview to ET NOW said 500 to 550 is what would be a fair value for Piramal Healthcare from current market perspective.

What about Piramal Healthcare, it is managing to sustain not too badly, up about 4%?

In terms of Piramal Healthcare, Sanofi-Aventis or Pfizer are in talks with the company. The company has denied it but the talks are very much there in the market-place and there should be some truth to it given the market moves. In terms of your fundamentals, it is overpriced as of now if we look at relative valuations to other healthcare companies. In terms of valuations, 500 to 550 is what I would think would be a fair value for the company from current market perspective, but given the news flow which is doing rounds about the deal happening, that is where the interest is clearly visible in this stock.